Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleVasculitis

The Role of Sural Nerve Biopsy in the Diagnosis of Vasculitis

Karl Gisslander, Lars B. Dahlin, Rona Smith, David Jayne, Dominic G. O’Donovan and Aladdin J. Mohammad
The Journal of Rheumatology September 2022, 49 (9) 1031-1036; DOI: https://doi.org/10.3899/jrheum.211406
Karl Gisslander
1K. Gisslander, MSc, Department of Rheumatology, Lund University, Lund, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karl Gisslander
  • For correspondence: karl.gisslander{at}med.lu.se
Lars B. Dahlin
2L.B. Dahlin, MD, PhD, Department of Translational Medicine - Hand Surgery, Lund University, Malmö, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lars B. Dahlin
Rona Smith
3R. Smith, MD, PhD, D. Jayne, MD, PhD, Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rona Smith
David Jayne
3R. Smith, MD, PhD, D. Jayne, MD, PhD, Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Jayne
Dominic G. O’Donovan
4D.G. O’Donovan, MD, Department of Neuropathology, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aladdin J. Mohammad
5A.J. Mohammad, MD, PhD, Department of Rheumatology, Lund University, Lund, Sweden, and Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aladdin J. Mohammad
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective The diagnostic yield of sural nerve biopsy (SNB) in vasculitis is uncertain. Our aim was to document relevant characteristics of patients undergoing SNB in the investigation of vasculitis; determine the diagnostic yield; relate positive biopsy findings to patient demographic, laboratory, and clinical variables; and to calculate the rate of surgical complications.

Methods Patients with suspected vasculitis that underwent SNB as part of diagnostic evaluation at academic medical centers in Sweden and the United Kingdom were identified by searching local pathology databases and clinic registers. A structured review of medical case records and pathology reports was conducted. Histological findings were categorized as definite, probable, or no vasculitis in accordance with the 2015 Brighton Collaboration reinterpretation and update of the Peripheral Nerve Society guidelines for vasculitic neuropathy. Definite and probable findings were considered positive for vasculitis.

Results Ninety-one patients that underwent SNB were identified (45% female). Forty (44%) patients showed histological evidence of vasculitis: 14 definite and 26 probable. A concomitant muscle biopsy conducted in 10 patients did not contribute to the diagnostic yield. Positive antineutrophil cytoplasmic antibody test, organ involvement other than the nervous system, and a longer biopsy sample were associated with a positive biopsy. The reported surgical complication rate was 15%.

Conclusion SNB of sufficient length is a useful procedure to confirm a diagnosis of vasculitis.

Key Indexing Terms:
  • antineutrophil cytoplasmic antibodies
  • biopsy
  • neurologic manifestations
  • vasculitis

Vasculitis of the peripheral nerves is a disorder characterized by inflammation of the vasa nervorum leading to ischemic damage to the affected nerve trunk.1 It may occur as part of a systemic disorder, most commonly antineutrophil cytoplasmatic antibody (ANCA)–associated vasculitis (AAV) or polyarteritis nodosa (PAN), or as a disorder restricted to the peripheral nervous system, such as single organ vasculitis or nonsystemic vasculitic neuropathy.2-4

There are no pathognomonic signs to confirm vasculitis. Clinical findings and laboratory/serology tests may provide guidance, but the diagnosis can be confirmed only by histology of an affected organ. The typical clinical manifestation of peripheral nerve vasculitis is acute onset of painful asymmetric sensorimotor neuropathy predominantly affecting a lower limb (mononeuritis multiplex), but clinical manifestations may vary.4 Clinical investigations in suspected cases of vasculitis include laboratory tests, medical imaging, and electrophysiological evaluation.

As in other organs affected by vasculitis, histological confirmation of active vasculitis is of high diagnostic value in suspected peripheral nerve vasculitis. Therefore, biopsy of an affected nerve is usually required. Confirmation of vasculitis is essential, as therapy includes immunosuppression with cytotoxic agents, biologics, and high doses of glucocorticoids (GCs), bringing associated risks of treatment toxicity.

The recommended nerve for biopsy varies among clinical centers and published reports.5-9 The biopsy specimen should preferably be obtained from a nerve identified as affected in the clinical or electrophysiological evaluation.10 This includes the superficial radial nerve, the dorsal cutaneous branch of the ulnar nerve, and the superficial peroneal nerve. However, the most commonly biopsied nerve is the sural nerve of the posterolateral lower leg.

The results of organ biopsy can be affected by aspects of sampling as well as length and representativeness of the collected specimen. As vasculitic lesions are distributed in a skip pattern along blood vessels, negative biopsies are common, even in the context of evident systemic disease. The estimated mean sensitivity of nerve biopsy in systemic vasculitis is 50%.4 The diagnostic yield of nerve biopsy in suspected vasculitis is uncertain, and published reports vary.5,9,11,12

Peripheral nerve biopsies are not without risk. Postsurgical sensory deficit is seen in a majority of patients, depending on the extent of preexisting neuropathy.13,14 Other less frequent adverse effects and sequelae include persistent postoperative pain, paresthesia, dysesthesia, and cold sensitivity.13-15 Surgical complications such as wound infection, wound dehiscence, delayed healing, and hematoma also occur rarely.14,15

In this study, we aimed to (1) record relevant characteristics of patients who underwent sural nerve biopsy (SNB) in conjunction with investigation for vasculitis at 2 academic medical centers; (2) estimate SNB diagnostic yield; (3) determine if there are differences between positive and negative biopsies regarding patient demographic, laboratory, and clinical variables; and (4) calculate the surgical procedure complication rate.

METHODS

Setting. A retrospective cohort study was conducted at Skåne University Hospital in Lund-Malmö, Sweden, and Addenbrooke’s Hospital in Cambridge, United Kingdom.

Patients. Patients that underwent peripheral nerve biopsy from 2005 through 2019 in Lund-Malmö, Sweden, were identified by searching the database of the Department of Pathology for the surgical procedure code ACW99, “other surgery of peripheral nerve,” using the Swedish Classification of Health Care Measures (KVÅ). Inclusion required a SNB referral based on a suspicion of vasculitis. Patients undergoing SNB at Addenbrooke’s Hospital between 2015 and 2019 were identified by searching the database of the Department of Pathology, using SNOMED-CT (Systematized Nomenclature of Medicine – Clinical Terms) “Structure of sural nerve (body structure) 82097001.” Cut-off dates were selected to simplify data collection by ensuring data were readily available in electronic records. Each study site generated a list of potentially eligible patients that were reviewed to ascertain eligibility.

Definitions of positive biopsy. Nerve biopsy specimens were processed as standard at the study sites. In order to enhance comparability, pathology results were assessed according to the 2015 Brighton Collaboration reinterpretation and update of the Peripheral Nerve Society guidelines for vasculitic neuropathy (Table 1).16,17 Pathology results were specified as definite, probable, or no vasculitis. Patients with biopsy showing either definite or probable vasculitis were combined to form 1 patient group that was considered as having a positive biopsy.

View this table:
  • View inline
  • View popup
Table 1.

Diagnostic criteria for histopathological definite and probable vasculitis.

View this table:
  • View inline
  • View popup

Data collection. A pro forma was designed for data collection. Baseline was defined as the day of the SNB. Laboratory data and clinical characteristics were collected, and results of the electrophysiological evaluation (nerve conduction studies [NCS] and/or electromyography) were recorded. Pathology reports were subjected to a structured review. When in-hospital follow-up information was available in the patient case records, the initiation time and dose of GC and/or immunosuppressive treatment was recorded. ANCA positivity was defined as ELISA positive for proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA. Information concerning surgical complications (wound infection, wound dehiscence, delayed wound healing and/or postsurgical hematoma) was recorded when available. Wound infection was defined as a condition requiring antibiotic treatment.

Statistical analysis. Categorical data are expressed as percentages, with differences tested using the chi-square test or Fisher exact test. Continuous variables are presented as mean and SD or as median and IQR, depending on the normality of distribution as shown by Shapiro-Wilk test. Differences of continuous variables were tested using t test or nonparametric Mann-Whitney U test. A P value of < 0.05 was considered significant. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp). The regional ethical review board for southern Sweden approved the study (LU 2015/51) and no informed consent of participants was required to be obtained. In accordance with the UK National Health Service Research Ethics Committee guidelines an ethical approval was not warranted as the study is retrospective and all treatment decisions were made prior to evaluation.

RESULTS

Patients. Of 346 (94 in Cambridge, 252 in Lund-Malmö) identified cases, 91 (34 Lund-Malmö, 57 Cambridge) fulfilled the study criteria and were included in the investigation. (Figure and Table 2). The mean age at the time of biopsy was 58 years (SD 15.02, range 20-84). Fifty (55%) of patients were male. The median duration of clinical symptoms attributed to vasculitis prior to biopsy was 8 months (IQR 4.75-24). Systemic organ involvement was more common in the Lund-Malmö cohort. The most commonly affected organ system apart from the nervous system was the skin, occurring in 17%, followed by mucous membranes and/or eyes (10%), pulmonary (9%), renal (8%), ear-nose-throat (ENT; 5%), cardiovascular (3%), and gastrointestinal (1%). Nerve conduction study was performed in 81 patients, and results of PR3-ANCA or MPO-ANCA analysis was available for 71 patients. Twenty (28%) patients were ANCA positive, 12 (17%) with PR3, and 8 (11%) with MPO antigen.

Flowchart of subjects meeting inclusion and exclusion criteria by study site.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure.

Flowchart of subjects meeting inclusion and exclusion criteria by study site.

View this table:
  • View inline
  • View popup
Table 2.

Characteristics of 91 patients undergoing sural nerve biopsy.

Assessment of biopsies. Two of the 91 patients, in addition to SNB, underwent simultaneous radial nerve biopsies: 1 of the superficial and 1 of the deep radial nerve branch. A concomitant muscle biopsy was performed in 10 patients: 9 of the quadriceps femoris muscle group and, in 1 case, of the peroneus muscle. A biopsy of the entire sural nerve was performed in 77 cases, while in 11 patients from the Lund-Malmö cohort, a fascicular biopsy was performed. In 3 cases it was unclear if a fascicular biopsy or a biopsy of the entire nerve was performed. The median length of the sural nerve sample was 22 mm (IQR 15-40). Definite vasculitis was reported in 14 patients (15%) and probable in 26 (29%), with no vasculitis found in 51 (56%). The radial nerve and muscle biopsies provided no additional diagnostic information.

Correlation of histology findings and disease characteristics. ANCA positivity (P = 0.03), suspected organ involvement in addition to the nervous system (P = 0.04), and greater length of biopsy sample (P = 0.04) were associated with positive biopsy findings (Table 3). No association was seen with PR3-ANCA or MPO-ANCA specificity (P = 0.15 and P = 0.13). In the electrophysiological evaluations, sensorimotor neuropathy was the most prevalent feature, occurring in 75% of patients. Pure motor or pure sensory symptoms were uncommon. No patient presenting with pure motor neuropathy showed a positive biopsy. Apparent axonal neuropathy in NCS was seen in 73% of the cohort. Biopsies were negative in the 2 patients presenting with demyelinating neuropathy. The remaining patients were not designated axonal or demyelinating neuropathy. In 66% of the electrophysiological reports, the pattern of neuropathy was described as patchy or asymmetric. However, no association of an electrophysiologically affected sural nerve or asymmetric electrophysiological pattern with a positive biopsy was found (Table 3).

View this table:
  • View inline
  • View popup
Table 3.

Clinical, neurophysiological, and surgical characteristics of patients with positive vs negative sural nerve biopsy for vasculitis.

Complications. Postsurgical follow-up information was available for 59 patients. Surgical complications arose in 9 (15%). The most common complication was wound infection (n = 6), followed by wound dehiscence (n = 4) and delayed wound healing (n = 3). A fascicular biopsy was not observed to reduce the surgical complication rate (P > 0.99), nor was a shorter biopsy sample (P = 0.18).

DISCUSSION

The comparability of our results with previously published studies of biopsy for the diagnosis of peripheral nerve vasculitis is limited by differences in vasculitis pathology criteria and unclearly described recruitment methods.5,12,18,19 In this study, histopathological vasculitis was categorized as definite or probable in accordance with the 2015 Brighton Collaboration reinterpretation and update of the Peripheral Nerve Society guidelines for vasculitic neuropathy,16,17 enabling comparability with future studies. Including cases with vessel wall inflammation, without necrosis but exhibiting other vasculitis-associated signs, increased sensitivity with only a marginal loss in specificity.20

The demographic features of our cohort were similar to those reported in other studies, with biopsies conducted in patients approximately 60 years of age after a relatively long duration of symptoms.5,9,12

A positive biopsy was associated with ANCA positivity and symptoms involving organs other than the nervous system. In a large European cohort of patients with AAV, vasculitic neuropathy was found in 28%, occurring more frequently in eosinophilic granulomatosis with polyangiitis than in microscopic polyangiitis or granulomatosis with polyangiitis, and in patients with MPO-ANCA than in PR3-ANCA.21

Neurologic involvement of systemic vasculitis is associated with cutaneous, mucous membrane/eye, and ENT involvement rather than the usually more severe manifestations such as pulmonary, cardiovascular, gastrointestinal, or renal symptoms.22 In our study, involvement of any organ outside the nervous system was associated with a positive biopsy result.

We found a rate of positive biopsies comparable to previous studies using similar definitions. Claussen et al,5 using a “definite and probable” definition as in our study, reported a positive SNB rate of 39% in patients with suspected vasculitis. Nathani et al,12 using diagnostic criteria similar to ours, identified definite vasculitis in 10% and probable vasculitis in 19% of patients with suspected vasculitis undergoing predominantly SNBs.

Biopsy of the superficial peroneal nerve combined with biopsy of the peroneus brevis muscle using a single incision has been suggested to provide greater diagnostic yield than SNB in suspected vasculitis.6,23 However, one should consider the greater risk of severe neurological sequelae.14 In our cohort, the muscle biopsy included in 10 of the 91 cases provided no additional diagnostic information, further confirming reports that no increase in diagnostic yield is seen with combined SNB and muscle biopsy.5,9 The majority of muscle biopsies in this study were taken from the quadriceps, as opposed to the more distal peroneus brevis muscle. It is possible, as hypothesized by Bennett et al,9 that distal predominance of muscle vasculitis or greater inflammation in muscles in the proximity of an affected nerve may result in enhanced diagnostic yield of combined superficial peroneal nerve and peroneus brevis biopsy.

We saw no association between being treated for vasculitis (GCs or immunosuppression) at the time of biopsy and a positive biopsy result. We hypothesized that treatment may have masked a positive biopsy result, explaining the relatively high proportion of negative biopsies. The effect of timing of treatment on biopsy result is unknown in SNB. In patients with suspected giant cell arteritis, a biopsy of the temporal artery still yields clinically useful information weeks after initiation of GC treatment.24

The finding of lack of association of an electrophysiological pattern with a positive biopsy result was unexpected. In accordance with previous descriptions of vasculitic neuropathy, the majority of patients included in this study experienced the typical pattern of sensory or sensorimotor axonal neuropathy.4 Four patients presented with pure motor neuropathy and 2 with demyelinating neuropathy on the NCS, with none exhibiting a positive biopsy. In 2 patients, SNB was performed despite a normal electrophysiological evaluation, due to clinical neuropathy. We did not observe the association of objective asymmetric neuropathy with a positive biopsy of the sural nerve that has previously been reported.12,25 It is feasible, given the long duration of symptoms prior to biopsy and the natural progression of vasculitic neuropathy, that the typical asymmetrical pattern in some positive cases has been blurred into a more symmetrical neuropathic distribution.4

We found length of the biopsy sample to be positively associated with diagnostic yield. This is not surprising, given the increased quantity of tissue for analysis, the skip lesion distribution of vasculitis along a blood vessel, and the asymmetry of axonal degeneration within an affected nerve.23,26 The importance of harvesting a suitable portion of the nerve with a sufficient number of intra-/extraneural microvessels must be stressed. Hence, an experienced surgeon should perform the procedure. The recommended length of the specimen10 is 50 mm. The median length of the samples in this study was 22 mm. The length of the sample may not, however, accurately reflect the length of the harvested nerve segment due to postresection shrinkage.27

Inconsistent information concerning the correlation of the length of the nerve resection and postsurgical sensory deficits has been reported.10,27 Due to our retrospective study design, information concerning subsequent sensory deficit was not available. However, residual deficits as well as additional symptoms have been reported in healthy subjects and in subjects with type 1 and 2 diabetes.13,28 In our study, 15% of patients for whom follow-up information was available experienced surgical complications, similar to previously reported rates.14,19 No positive relationship was observed between surgical complication rate and length of biopsy specimen, which was generally short.

Our study has limitations. Due to its retrospective nature, missing data may have affected the assessment of correlation between biopsy findings and clinical characteristics, as well as the rate of surgical complications. This also precluded us from investigating predictors of a positive biopsy by fitting a multivariable regression model.

Strengths of this study include using a well-defined definition of biopsy positive for vasculitis. In addition, investigating SNB at 2 academic centers in different countries enabled us to include, in the context of vasculitic neuropathy, a relatively large number of patients.

In conclusion, SNB should be of sufficient length and include the relevant intraneural blood vessels. Routine conduction of combined muscle biopsy and SNB is not recommended. A thorough clinical examination should be done before performing SNB, and may guide you in the usefulness of the procedure. A SNB of sufficient length is of value in confirming a diagnosis of vasculitis.

ACKNOWLEDGMENT

We thank Mr. Simon Brown, for searching the pathology database at Addenbrooke’s Hospital, Cambridge, UK.

Footnotes

  • This study was supported by grants from the Swedish Research Council (Vetenskapsrådet: 2019-01655), and the Faculty of Medicine, Lund University (ALF-medel).

  • The authors declare no conflicts of interest related to this article.

  • Accepted for publication May 17, 2022.
  • Copyright © 2022 by the Journal of Rheumatology

REFERENCES

  1. 1.↵
    1. Graf J,
    2. Imboden J.
    Vasculitis and peripheral neuropathy. Curr Opin Rheumatol 2019;31:40–5.
    OpenUrlCrossRef
  2. 2.↵
    1. Gwathmey KG,
    2. Burns TM,
    3. Collins MP,
    4. Dyck PJ.
    Vasculitic neuropathies. Lancet Neurol 2014;13:67–82.
    OpenUrlCrossRefPubMed
  3. 3.
    1. Gwathmey KG,
    2. Tracy JA,
    3. Dyck PJB.
    Peripheral nerve vasculitis: classification and disease associations. Neurol Clin 2019;37:303–33.
    OpenUrl
  4. 4.↵
    1. Collins MP,
    2. Hadden RD.
    The nonsystemic vasculitic neuropathies. Nat Rev Neurol 2017;13:302–16.
    OpenUrlPubMed
  5. 5.↵
    1. Claussen GC,
    2. Thomas TD,
    3. Goyne C,
    4. Vázquez LG,
    5. Oh SJ.
    Diagnostic value of nerve and muscle biopsy in suspected vasculitis cases. J Clin Neuromuscul Dis 2000;1:117–23.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Vital C,
    2. Vital A,
    3. Canron MH, et al.
    Combined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases. J Peripher Nerv Syst 2006;11:20–9.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Prada V,
    2. Massucco S,
    3. Venturi C, et al.
    Diagnostic Value of Sural Nerve Biopsy: Retrospective Analysis of Clinical Cases From 1981 to 2017. Front Neurol 2019;10:1218.
    OpenUrl
  8. 8.
    1. Agadi JB,
    2. Raghav G,
    3. Mahadevan A,
    4. Shankar SK.
    Usefulness of superficial peroneal nerve/peroneus brevis muscle biopsy in the diagnosis of vasculitic neuropathy. J Clin Neurosci 2012;19:1392–6.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Bennett DL,
    2. Groves M,
    3. Blake J, et al.
    The use of nerve and muscle biopsy in the diagnosis of vasculitis: a 5 year retrospective study. J Neurol Neurosurg Psychiatry 2008;79:1376–81.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Weis J,
    2. Brandner S,
    3. Lammens M,
    4. Sommer C,
    5. Vallat JM.
    Processing of nerve biopsies: a practical guide for neuropathologists. Clin Neuropathol 2012;31:7–23.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Dyck PJ,
    2. Benstead TJ,
    3. Conn DL,
    4. Stevens JC,
    5. Windebank AJ,
    6. Low PA.
    Nonsystemic vasculitic neuropathy. Brain 1987;110:843–53.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Nathani D,
    2. Barnett MH,
    3. Spies J,
    4. Pollard J,
    5. Wang MX,
    6. Kiernan MC.
    Vasculitic neuropathy: comparison of clinical predictors with histopathological outcome. Muscle Nerve 2019;59:643–9.
    OpenUrl
  13. 13.↵
    1. Dahlin LB,
    2. Eriksson KF,
    3. Sundkvist G.
    Persistent postoperative complaints after whole sural nerve biopsies in diabetic and non-diabetic subjects. Diabet Med 1997;14:353–6.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Hilton DA,
    2. Jacob J,
    3. Househam L,
    4. Tengah C.
    Complications following sural and peroneal nerve biopsies. J Neurol Neurosurg Psychiatry 2007;78:1271–2.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Ruth A,
    2. Schulmeyer FJ,
    3. Roesch M,
    4. Woertgen C,
    5. Brawanski A.
    Diagnostic and therapeutic value due to suspected diagnosis, long-term complications, and indication for sural nerve biopsy. Clin Neurol Neurosurg 2005;107:214–7.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Collins MP,
    2. Dyck PJ,
    3. Gronseth GS, et al.
    Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Peripher Nerv Syst 2010;15:176–84.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Hadden RDM,
    2. Collins MP,
    3. Živković SA, et al.
    Vasculitic peripheral neuropathy: case definition and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine 2017;35:1567–78.
    OpenUrlPubMed
  18. 18.↵
    1. Luigetti M,
    2. Di Paolantonio A,
    3. Bisogni G, et al.
    Sural nerve biopsy in peripheral neuropathies: 30-year experience from a single center. Neurol Sci 2020;41:341–6.
    OpenUrl
  19. 19.↵
    1. Rappaport WD,
    2. Valente J,
    3. Hunter GC, et al.
    Clinical utilization and complications of sural nerve biopsy. Am J Surg 1993;166:252–6.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Collins MP,
    2. Mendell JR,
    3. Periquet MI, et al.
    Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000;55:636–43.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Bischof A,
    2. Jaeger VK,
    3. Hadden RDM, et al.
    Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: insights from the DCVAS study. Neurol Neuroimmunol Neuroinflamm 2019;6:e615.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Suppiah R,
    2. Hadden RD,
    3. Batra R, et al; European Vasculitis Study Group
    . Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology 2011;50:2214–22.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Said G,
    2. Lacroix-Ciaudo C,
    3. Fujimura H,
    4. Blas C,
    5. Faux N.
    The peripheral neuropathy of necrotizing arteritis: a clinicopathological study. Ann Neurol 1988;23:461–5.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Jakobsson K,
    2. Jacobsson L,
    3. Mohammad AJ, et al.
    The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC Musculoskelet Disord 2016;17:363.
    OpenUrl
  25. 25.↵
    1. Zivković SA,
    2. Ascherman D,
    3. Lacomis D.
    Vasculitic neuropathy--electrodiagnostic findings and association with malignancies. Acta Neurol Scand 2007;115:432–6.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Morozumi S,
    2. Koike H,
    3. Tomita M, et al.
    Spatial distribution of nerve fiber pathology and vasculitis in microscopic polyangiitis-associated neuropathy. J Neuropathol Exp Neurol 2011;70:340–8.
    OpenUrl
  27. 27.↵
    1. Theriault M,
    2. Dort J,
    3. Sutherland G,
    4. Zochodne DW.
    A prospective quantitative study of sensory deficits after whole sural nerve biopsies in diabetic and nondiabetic patients. Surgical approach and the role of collateral sprouting. Neurology 1998;50:480–4.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Dahlin LB,
    2. Lithner F,
    3. Bresäter LE,
    4. Thomsen NO,
    5. Eriksson KF,
    6. Sundkvist G.
    Sequelae following sural nerve biopsy in type 1 diabetic subjects. Acta Neurol Scand 2008;118:193–7.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 49, Issue 9
1 Sep 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Role of Sural Nerve Biopsy in the Diagnosis of Vasculitis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Role of Sural Nerve Biopsy in the Diagnosis of Vasculitis
Karl Gisslander, Lars B. Dahlin, Rona Smith, David Jayne, Dominic G. O’Donovan, Aladdin J. Mohammad
The Journal of Rheumatology Sep 2022, 49 (9) 1031-1036; DOI: 10.3899/jrheum.211406

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Role of Sural Nerve Biopsy in the Diagnosis of Vasculitis
Karl Gisslander, Lars B. Dahlin, Rona Smith, David Jayne, Dominic G. O’Donovan, Aladdin J. Mohammad
The Journal of Rheumatology Sep 2022, 49 (9) 1031-1036; DOI: 10.3899/jrheum.211406
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Keywords

ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES
BIOPSY
NEUROLOGIC MANIFESTATIONS
VASCULITIS

Related Articles

Cited By...

More in this TOC Section

  • The Natural History of Deficiency of Adenosine Deaminase 2 Vasculitis in a Large Cohort and Factors Associated With Disease-Related Damage
  • Navigating the Roadblocks: National Patient and Provider Survey on Barriers to Healthcare and Medication Access for Patients With Vasculitis
  • Assessment of Giant Cell Arteritis–Associated Visual Outcomes at a Tertiary Hospital in Ontario, Canada
Show more Vasculitis

Similar Articles

Keywords

  • ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES
  • BIOPSY
  • NEUROLOGIC MANIFESTATIONS
  • vasculitis

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire